Monoclonal Antibody Therapies

Due to the specificity of monoclonal antibodies, their use for long-term treatment of viral infections is increasingly becoming a topic of research by scientists. Diseases such as Cancer, Rheumatoid Arthritis, and viruses such as HIV and Hepatitis C are possible targets for monoclonal antibody therapy. Since a monoclonal antibody (mAB) has one specific antigen target, when administered to infected persons or organisms, they behave similarly to a vaccination and may produce long-lasting protective antiviral effects. Originally mABs were used by scientists for the direct neutralization and elimination of viruses, but more recently, with the discovery that mABs may be able to recognize cell proteins from cells infected by the virus, scientists are hopeful that full scale recovery is possible even from a possibly fatal viral infection. The ability for mABs to bind to infected cells by recognizing viral proteins on the cell membrane has been shown effective in mice, but more research must be done to see if similar, potentially life saving effects can be proven in humans.
Source: http://www.sciencedaily.com/releases/2010/06/100611124651.htm


Aviva Systems Biology manufactures and sells premium products including antibodies, reagents for ELISA, western blotting, and immunofluorescence, and recombinant proteins, for your research needs. Aviva has the capacity to produce 600 targets each month enabling us to provide 200 new antibodies every month to add to our growing catalog of over 8,000 antibodies. ASB produces high quality antibodies by our process of selecting more than two epitope-derived peptides for each target protein and using multiple human tissues or cell lines for testing of native expression of antigen. ASB provides a full warranty for quality of our antibodies, since they are manufactured and vigorously tested by ELISA, peptide based Western Blots, and IHC before release. Our goal is to provide you with the BEST access to high quality antibodies.